SCHEMBL1665310

SCHEMBL1665310

Cc1ccc(O)cc1CO

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SHBG P04278 1/20 0.47
CYP3A4 P08684 2/20 0.45
TSHR P16473 1/20 0.45
RECQL P46063 1/20 0.45
ACHE P22303 1/20 0.45
ESR2 Q92731 4/20 0.42
HSD17B1 P14061 1/20 0.40
PKM P14618 1/20 0.39
TYR P14679 1/20 0.39
ESR1 P03372 3/20 0.38
HPGD P15428 1/20 0.37
CHRM1 P11229 1/20 0.37
ALOX15 P16050 1/20 0.37
MAOA P21397 1/20 0.37
TBXA2R P21731 1/20 0.37
ADRA1A P35348 1/20 0.37
HTR2B P41595 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6266185 0.83 CYP3A4 (0.47) CYP3A4TSHRRECQLACHEESR2
SCHEMBL2015021 0.81 CYP3A4 (0.50) SHBGCYP3A4TSHRRECQLACHE
SCHEMBL31305638 0.81 CYP3A4 (0.50) SHBGCYP3A4TSHRRECQLACHE
SCHEMBL41776 0.81 ESR2 (0.47) SHBGCYP3A4TSHRRECQLACHE
SCHEMBL7755506 0.79 TSHR (0.44) CYP3A4TSHRRECQLACHEESR2
SCHEMBL19735194 0.79 CYP3A4 (0.44) CYP3A4TSHRRECQLACHEESR2
SCHEMBL1663206 0.79 CYP3A4 (0.44) CYP3A4TSHRRECQLACHEESR2
SCHEMBL148755 0.78 SHBG (0.48) SHBGTSHRRECQLESR2PKM
SCHEMBL29741490 0.78 SHBG (0.48) SHBGTSHRRECQLESR2PKM
SCHEMBL92914 0.78 TAAR1 (0.56) SHBGTSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365588-B2 Benzoxazines as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-06-14 US disclosed
CN-102666545-B As the heterocycle Pyrazolopyrimidine analogs of JAK inhibitor CELLZOME LTD. (GB) 2016-04-06 CN disclosed
US-9242987-B2 Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors CELLZOME LIMITED (GB) 2016-01-26 US disclosed
US-20140309220-A1 BENZOXAZINES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2014-10-16 US disclosed
US-20140171427-A1 Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-06-19 US disclosed
EP-2691432-A2 A TWO-COAT BARRIER SYSTEM COMPRISING POLYURETHANE Sun Chemical B.V. (NL) 2014-02-05 EP disclosed
WO-2013067248-A1 BENZOXAZINES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-10 WO disclosed
US-20120252779-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2012-10-04 US disclosed
WO-2012131362-A2 A TWO-COAT BARRIER SYSTEM COMPRISING POLYURETHANE SUN CHEMICAL B.V. (NL) 2012-10-04 WO disclosed
CN-102666545-A Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors CELLZOME LTD 2012-09-12 CN disclosed
CN-101070316-A Diaryl acid derivatives as PPAR receptor ligands AVENTIS PHARMA GMBH (DE) 2007-11-14 CN disclosed
CN-1331862-C Diaryl acid derivatives as PPAR receptor ligands AVENTIS PHARAMCEUTICALS PRODUC (DE) 2007-08-15 CN disclosed
WO-2006074924-A1 3,4,(5)-SUBSTITUTED TETRAHVDROPYRIDINES NOVARTIS AG (CH) 2006-07-20 WO disclosed
US-6635655-B1 Agonists or antagonists of peroxisome proliferator-activated receptors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-10-21 US disclosed
US-6376512-B1 FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-23 US disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed
WO-1989004305-A1 QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 RORER INTERNATIONAL (OVERSEAS) INC. (US) 1989-05-18 WO disclosed
US-4778757-A ADDING FIRST REAGENT OF OXIDASE, PEROXIDASE AND PHENOLIC CHROMOGEN FOLLOWED BY ADDING COUPLER; ACCURATE COLORIMETRY TOYO BOSEKI KABUSHIKI KAISHA (JP) 1988-10-18 US disclosed
US-4306083-A Multiphase oxidation of alcohol to aldehyde THE DOW CHEMICAL COMPANY (US) 1981-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252779-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS JAK1, JAK3, JAK2 SHBG 4369/4885CYP3A4 794/4885TSHR 2253/4885
US-20140171427-A1 Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels KCNJ2, TRPV1, KCNJ1 SHBG 4849/4885CYP3A4 2842/4885TSHR 1172/4885
US-20140309220-A1 BENZOXAZINES AS MODULATORS OF ION CHANNELS KCNJ1, KCNJ2, KCNJ11 SHBG 4694/4885CYP3A4 979/4885TSHR 3107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.